Promising New Sepsis Treatment on the Horizon
The BHF Translational Award was granted to Dr. James Leiper and his clinical collaborator Dr. Simon Lambden at the Medical Research Council Clinical Sciences Centre (MRC CSC). It will cover the costs of further studies to find different forms of a drug candidate the Centre is developing to treat the dangerous effects of sepsis. One of these new forms could then be taken into clinical trials.
Early funding for the research, awarded back in 2002, also came from the BHF. This funding supported the laboratory animal research where the discovery was made of the potential of L-257. The drug works by reducing the production of the chemical nitric oxide. Healthy amounts of nitric oxide are needed for the normal function of blood vessels. However, during sepsis high nitric oxide levels can cause dangerously low blood pressure and ultimately organ failure.
Based on lab test results, the researchers are confident L-257 will be safe and effective at treating sepsis in people. “After over a decade of hard work in the lab, it’s exciting to see this promising drug is getting closer to helping thousands of people a year,” says Dr. Leiper, who is leading this new BHF-funded research at the MRC CSC.
See Also: Algorithm Helps Predict Patients' Deadly Sepsis
In the UK, each year more than 100,000 people are admitted to hospital due to sepsis, a life-threatening condition caused by an infection. However, over a third (around 37,000) of those people die. Antibiotics can effectively treat the infection, but the body’s response to the infection can cause dangerously low blood pressure, organ failure and death. An effective treatment for this aspect of sepsis is urgently needed and many drugs have already failed to make it through clinical trials.
“Developing treatments for sepsis has been called the ‘graveyard for pharmaceutical companies’ because people with sepsis are often in a highly unstable condition. This can make it very difficult to detect whether a treatment is working," Dr. Leiper explains. "Therefore clinical trials for sepsis treatments often end up being very large and very expensive. But with the BHF’s support we should be able to reduce these risks, and make L-257 a very attractive product for taking into clinical trials."
According to Professor Peter Weissberg, Medical Director at the British Heart Foundation: “It’s not realistic for charities to take on the costs and risk associated with taking a new drug or test through clinical trials. But we can help make lab research, like Dr. Leiper’s which we’ve funded over many years, attractive enough for pharmaceutical companies to take on that risk and cost.”
Source and image credit: MRC Clinical Sciences Centre, Imperial College London
Published on : Mon, 23 Nov 2015
Intended for emergency airway access when conventional endotracheal intubation cannot be performed. Features and benefits The catheter is coil reinforced to prevent kinking. Emergency Transtracheal Airway Catheter procedural...
Intended for emergency transtracheal catheter ventilation when conventional ventilation by mask or endotracheal tube cannot be performed. Features and benefits The set provides clinicians with a compact solution for quickly establishing...
Designed for many applications. Venue is a multi-purpose, point of care system that is also well-suited to help you manage patients in shock. It includes automated tools that enable you to quickly get the information you need to make fast decisions...
The system is easy to use and delivers incredibly fast, accurate, and standardized results with minimal centrifugation time of five minutes. Beyond Results. Confidence. Leverage the comprehensive power of Ortho’s trusted testing menu....
The power of B•R•A•H•M•S with the difference that only VITROS ® can deliver B•R•A•H•M•S PCT is the best biomarker for early bacterial Sepsis Sepsis is a life threatening condition where the body overreacts to an infection. I